Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: A focus on the cardiomyocyte

Clinical Science

Volumn 125, Issue 9, 2013, Pages 409-421

  Bienvenu, Laura A ^a,b   Reichelt, Melissa E ^b   Delbridge, Lea M D ^b   Young, Morag J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aldosterone; Cardiac function; Glucocorticoid; Hypertension; Inflammation; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; COLLAGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; POTASSIUM;

ALDOSTERONE BLOOD LEVEL; APOPTOSIS; ARTICLE; CALCIUM CURRENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHROMATIN; CORONARY ARTERY LIGATION; CYTOPLASM; CYTOSOL; DIASTOLIC DYSFUNCTION; DISEASE COURSE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HORMONE RESPONSIVE ELEMENT; HUMAN; HYPERTENSION; INFLAMMATION; LIGAND BINDING; MACROPHAGE; MORBIDITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; FEMALE; FIBROSIS; HEART FAILURE; HUMANS; MACROPHAGES; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; SEX FACTORS; SIGNAL TRANSDUCTION;

EID: 84880695716     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130050     Document Type: Article

References (150)

1. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J. and Gatlin, M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321
2. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717
3. Wynn, T. A. (2008) Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210
4. Young, M. J., Lam, E. Y. and Rickard, A. J. (2007) Mineralocorticoid receptor activation and cardiac fibrosis. Clin. Sci. 112, 467-475
5. Brilla, C. G., Matsubara, L. S. and Weber, K. T. (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am. J. Cardiol. 71, 12A-16A
6. Arriza, J. L., Simerly, R. B., Swanson, L. W. and Evans, R. M. (1988) The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron 1, 887-900
7. Pearce, P. and Funder, J. W. (1987) High affinity aldosterone binding sites (type I receptors) in rat heart. Clin. Exp. Pharmacol. Physiol. 14, 859-866
8. Lombes, M., Oblin, M. E., Gasc, J. M., Baulieu, E. E., Farman, N. and Bonvalet, J. P. (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res. 71, 503-510
9. Lombes, M., Alfaidy, N., Eugene, E., Lessana, A., Farman, N. and Bonvalet, J. P. (1995) Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 ß-hydroxysteroid dehydrogenase in the human heart. Circulation 92, 175-182
10. Sheppard, K. E. and Autelitano, D. J. (2002) 11ß-Hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 143, 198-204
11. Odermatt, A. and Kratschmar, D. V. (2012) Tissue-specific modulation of mineralocorticoid receptor function by 11ß-hydroxysteroid dehydrogenases: an overview. Mol. Cell. Endocrinol. 350, 168-186
12. Yang, J. and Young, M. J. (2009) The mineralocorticoid receptor and its coregulators. J. Mol. Endocrinol. 43, 53-64
13. Hernandez-Diaz, I., Giraldez, T., Arnau, M. R., Smits, V. A., Jaisser, F., Farman, N. and Alvarez de la Rosa, D. (2010) The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology 151, 3888-3899
14. Gomez-Sanchez, C. E., de Rodriguez, A. F., Romero, D. G., Estess, J., Warden, M. P., Gomez-Sanchez, M. T. and Gomez-Sanchez, E. P. (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147, 1343-1348
15. Wehling, M., Neylon, C. B., Fullerton, M., Bobik, A. and Funder, J. W. (1995) Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ. Res. 76, 973-979
16. Wehling, M., Eisen, C. and Christ, M. (1992) Aldosterone-specific membrane receptors and rapid non-genomic actions of mineralocorticoids. Mol. Cell. Endocrinol. 90, C5-C9
17. Dooley, R., Harvey, B. J. and Thomas, W. (2012) Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol. Cell. Endocrinol. 350, 223-234 18 Funder, J. W. (2005) The nongenomic actions of aldosterone. Endocr. Rev. 26, 313-321
18. Funder, J. W. (2005) The nongenomic actions of aldosterone. Endocr. Rev. 26, 313-321
19. Harvey, B. J., Alzamora, R., Stubbs, A. K., Irnaten, M., McEneaney, V. and Thomas, W. (2008) Rapid responses to aldosterone in the kidney and colon. J. Steroid Biochem. Mol. Biol. 108, 310-317
20. Thomas, W., McEneaney, V. and Harvey, B. J. (2008) Aldosterone-induced signalling and cation transport in the distal nephron. Steroids 73, 979-984
21. Thomas, W. and Harvey, B. J. (2011) Mechanisms underlying rapid aldosterone effects in the kidney. Annu. Rev. Physiol. 73, 335-357
22. Gros, R., Ding, Q., Davis, M., Shaikh, R., Liu, B., Chorazyczewski, J., Pickering, J. G. and Feldman, R. D. (2011) Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Can. J. Physiol. Pharmacol. 89, 655-663
23. Funder, J. W. (2011) GPR30, mineralocorticoid receptors, and the rapid vascular effects of aldosterone. Hypertension 57, 370-372
24. Gros, R., Ding, Q., Sklar, L. A., Prossnitz, E. E., Arterburn, J. B., Chorazyczewski, J. and Feldman, R. D. (2011) GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 57, 442-451
25. Wendler, A., Albrecht, C. and Wehling, M. (2012) Nongenomic actions of aldosterone and progesterone revisited. Steroids 77, 1002-1006
26. Deschamps, A. M., Murphy, E. and Sun, J. (2010) Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med. 20, 73-78
27. Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E. and Evans, R. M. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268-275
28. Stewart, P. M., Whorwood, C. B., Barber, P., Gregory, J., Monder, C., Franklyn, J. A. and Sheppard, M. C. (1991) Localization of renal 11 ß-dehydrogenase by in situ hybridization: autocrine not paracrine protector of the mineralocorticoid receptor. Endocrinology 128, 2129-2135
29. Edwards, C. R., Stewart, P. M., Burt, D., Brett, L., McIntyre, M. A., Sutanto, W. S., de Kloet, E. R. and Monder, C. (1988) Localisation of 11 ß-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 2, 986-989
30. Funder, J. W., Pearce, P. T., Smith, R. and Smith, A. I. (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583-585
31. Albiston, A. L., Obeyesekere, V. R., Smith, R. E. and Krozowski, Z. S. (1994) Cloning and tissue distribution of the human 11 ß-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105, R11-R17
32. Krozowski, Z. S., Provencher, P. H., Smith, R. E., Obeyesekere, V. R., Mercer, W. R. and Albiston, A. L. (1994) Isozymes of 11 ß-hydroxysteroid dehydrogenase: which enzyme endows mineralocorticoid specificity? Steroids 59, 116-120
33. Berger, S., Wolfer, D. P., Selbach, O., Alter, H., Erdmann, G., Reichardt, H. M., Chepkova, A. N., Welzl, H., Haas, H. L., Lipp, H. P. and Schutz, G. (2006) Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc. Natl. Acad. Sci. U.S.A. 103, 195-200
34. Funder, J. and Myles, K. (1996) Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137, 5264-5268
35. Funder, J. W. (2009) Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286-290
36. Ward, M. R., Kanellakis, P., Ramsey, D., Funder, J. and Bobik, A. (2001) Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104, 467-472
37. Wilson, P., Morgan, J., Funder, J. W., Fuller, P. J. and Young, M. J. (2009) Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin. Sci. 116, 731-739
38. Farman, N. and Rafestin-Oblin, M. E. (2001) Multiple aspects of mineralocorticoid selectivity. Am. J. Physiol. Renal Physiol. 280, F181-F192
39. Rogerson, F. M. and Fuller, P. J. (2003) Interdomain interactions in the mineralocorticoid receptor. Mol. Cell. Endocrinol. 200, 45-55
40. Pippal, J. B. and Fuller, P. J. (2008) Structure-function relationships in the mineralocorticoid receptor. J. Mol. Endocrinol. 41, 405-413
41. Ahmed, A., Zannad, F., Love, T. E., Tallaj, J., Gheorghiade, M., Ekundayo, O. J. and Pitt, B. (2007) A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur. Heart J. 28, 1334-1343
42. Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R. A., Roniker, B., Kleiman, J., Krause, S., Burns, D. and Williams, G. H. (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108, 1831-1838
43. Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J. and Pitt, B. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21
44. Preiss, D., van Veldhuisen, D. J., Sattar, N., Krum, H., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 14, 909-915
45. Zannad, F., McMurray, J. J., Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 12, 617-622
46. Swedberg, K., Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 59, 1598-1603
47. Catena, C., Colussi, G., Brosolo, G., Iogna-Prat, L. and Sechi, L. A. (2012) Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. Am. J. Cardiovasc. Dis. 2, 50-57
48. Deswal, A., Richardson, P., Bozkurt, B. and Mann, D. L. (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J. Card. Fail. 17, 634-642
49. de Simone, G., Chinali, M., Mureddu, G. F., Cacciatore, G., Lucci, D., Latini, R., Masson, S., Vanasia, M., Maggioni, A. P. and Boccanelli, A. (2011) Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutr., Metab. Cardiovasc. Dis. 21, 783-791
50. Mottram, P. M., Haluska, B., Leano, R., Cowley, D., Stowasser, M. and Marwick, T. H. (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110, 558-565
51. Barfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Perez, S., Heckroth, H., Nitsche, A., Erguden, J. K., Gielen-Haertwig, H., Schlemmer, K. H. et al. (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7, 1385-1403
52. Pitt, B., Filippatos, G., Gheorghiade, M., Kober, L., Krum, H., Ponikowski, P., Nowack, C., Kolkhof, P., Kim, S. Y. and Zannad, F. (2012) Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur. J. Heart Fail. 14, 668-675
53. Tsai, C. T., Chiang, F. T., Tseng, C. D., Hwang, J. J., Kuo, K. T., Wu, C. K., Yu, C. C., Wang, Y. C., Lai, L. P. and Lin, J. L. (2010) Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J. Am. Coll. Cardiol. 55, 758-770
54. Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R. and Sechi, L. A. (2008) Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80-85
55. Milliez, P., Girerd, X., Plouin, P. F., Blacher, J., Safar, M. E. and Mourad, J. J. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243-1248
56. Dabrowski, R., Borowiec, A., Smolis-Bak, E., Kowalik, I., Sosnowski, C., Kraska, A., Kazimierska, B., Wozniak, J., Zareba, W. and Szwed, H. (2010) Effect of combined spironolactone-beta-blocker+- enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am. J. Cardiol. 106, 1609-1614
57. Wei, J., Ni, J., Huang, D., Chen, M., Yan, S. and Peng, Y. (2010) The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin. Cardiol. 33, 572-577
58. Leuzzi, C., Sangiorgi, G. M. and Modena, M. G. (2010) Gender-specific aspects in the clinical presentation of cardiovascular disease. Fundam. Clin. Pharmacol. 24, 711-717
59. Dunlay, S. M. and Roger, V. L. (2012) Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr. Heart Fail. Rep. 9, 267-276
60. Hayward, C. S., Kelly, R. P. and Collins, P. (2000) The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc. Res. 46, 28-49
61. Mendelsohn, M. E. and Karas, R. H. (2005) Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583-1587
62. Mehilli, J., Ndrepepa, G., Kastrati, A., Nekolla, S. G., Markwardt, C., Bollwein, H., Pache, J., Martinoff, S., Dirschinger, J., Schwaiger, M. and Schomig, A. (2005) Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. J. Am. Coll. Cardiol. 45, 828-831
63. Diedrich, M., Tadic, J., Mao, L., Wacker, M. A., Nebrich, G., Hetzer, R., Regitz-Zagrosek, V. and Klose, J. (2007) Heart protein expression related to age and sex in mice and humans. Int. J. Mol. Med. 20, 865-874
64. Jochmann, N., Stangl, K., Garbe, E., Baumann, G. and Stangl, V. (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur. Heart J. 26, 1585-1595
65. Waxman, D. J. and Holloway, M. G. (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 76, 215-228
66. Pouleur, A. C., Uno, H., Prescott, M. F., Desai, A., Appelbaum, E., Lukashevich, V., Smith, B. A., Dahlof, B. and Solomon, S. D. (2011) Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J. Renin Angiotensin Aldosterone Syst. 12, 483-490
67. Rocha, R., Martin-Berger, C. L., Yang, P., Scherrer, R., Delyani, J. and McMahon, E. (2002) Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143, 4828-4836
68. Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A., McMahon, E. G. and Delyani, J. A. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810
69. Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T. and Weber, K. T. (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161, 1773-1781
70. Noda, K., Kobara, M., Hamada, J., Yoshifuji, Y., Shiraishi, T., Tanaka, T., Wang, J., Toba, H. and Nakata, T. (2012) Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J. Cardiovasc. Pharmacol. 60, 140-149
71. Nagase, M., Ayuzawa, N., Kawarazaki, W., Ishizawa, K., Ueda, K., Yoshida, S. and Fujita, T. (2012) Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 59, 500-506
72. Fraccarollo, D., Berger, S., Galuppo, P., Kneitz, S., Hein, L., Schutz, G., Frantz, S., Ertl, G. and Bauersachs, J. (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408
73. Rickard, A. J., Morgan, J., Bienvenu, L. A., Fletcher, E. K., Cranston, G. A., Shen, J. Z., Reichelt, M. E., Delbridge, L. M. and Young, M. J. (2012) Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension 60, 1443-1450
74. Lother, A., Berger, S., Gilsbach, R., Rosner, S., Ecke, A., Barreto, F., Bauersachs, J., Schutz, G. and Hein, L. (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57, 746-754
75. Favre, J., Gao, J., Zhang, A. D., Remy-Jouet, I., Ouvrard-Pascaud, A., Dautreaux, B., Escoubet, B., Thuillez, C., Jaisser, F. and Richard, V. (2011) Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am. J. Physiol. Heart Circ. Physiol. 300, H2035-H2043
76. Shen, J. Z. and Young, M. J. (2012) Corticosteroids, heart failure, and hypertension: a role for immune cells? Endocrinology 153, 5692-5700
77. Rickard, A. J., Morgan, J., Tesch, G., Funder, J. W., Fuller, P. J. and Young, M. J. (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54, 537-543
78. Bienvenu, L. A., Morgan, J., Rickard, A. J., Tesch, G. H., Cranston, G. A., Fletcher, E. K., Delbridge, L. M. and Young, M. J. (2012) Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153, 3416-3425
79. Usher, M. G., Duan, S. Z., Ivaschenko, C. Y., Frieler, R. A., Berger, S., Schutz, G., Lumeng, C. N. and Mortensen, R. M. (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 120, 3350-3364
80. Rickard, A. J. and Young, M. J. (2009) Corticosteroid receptors, macrophages and cardiovascular disease. J. Mol. Endocrinol. 42, 449-459
81. Barnes, P. J. (2011) Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 163, 29-43
82. Biddie, S. C., Conway-Campbell, B. L. and Lightman, S. L. (2012) Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatology 51, 403-412
83. Qin, W., Rudolph, A. E., Bond, B. R., Rocha, R., Blomme, E. A., Goellner, J. J., Funder, J. W. and McMahon, E. G. (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 93, 69-76
84. Mihailidou, A. S. and Funder, J. W. (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70, 347-351
85. Rossier, M. F., Lenglet, S., Vetterli, L., Python, M. and Maturana, A. (2008) Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52, 721-728
86. Latouche, C., Sainte-Marie, Y., Steenman, M., Castro Chaves, P., Naray-Fejes-Toth, A., Fejes-Toth, G., Farman, N. and Jaisser, F. (2010) Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 151, 4467-4476
87. Messaoudi, S., Gravez, B., Tarjus, A., Pelloux, V., Ouvrard-Pascaud, A., Delcayre, C., Samuel, J., Launay, J. M., Sierra-Ramos, C., Alvarez de la Rosa, D. et al. (2013) Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 61, 361-367
88. Brilla, C. G. and Weber, K. T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901
89. Young, M., Fullerton, M., Dilley, R. and Funder, J. (1994) Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93, 2578-2583
90. Weber, K. T. (2001) Aldosterone in congestive heart failure. N. Engl. J. Med. 345, 1689-1697
91. Young, M., Head, G. and Funder, J. (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269, E657-E662
92. Young, M. and Funder, J. W. (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145, 3153-3157
93. Robert, V., Silvestre, J. S., Charlemagne, D., Sabri, A., Trouve, P., Wassef, M., Swynghedauw, B. and Delcayre, C. (1995) Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26, 971-978
94. Fujisawa, G., Dilley, R., Fullerton, M. J. and Funder, J. W. (2001) Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142, 3625-3631
95. Weber, K. T. (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 13, 1637-1652
96. Swynghedauw, B. (1999) Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79, 215-262
97. Lijnen, P. and Petrov, V. (2000) Induction of cardiac fibrosis by aldosterone. J. Mol. Cell Cardiol. 32, 865-879
98. Young, M. J. and Funder, J. W. (1996) Mineralocorticoids, salt, hypertension: effects on the heart. Steroids 61, 233-235
99. du Cailar, G., Fesler, P., Ribstein, J. and Mimran, A. (2010) Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 56, 865-870
100. Baylis, C., Mitruka, B. and Deng, A. (1992) Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90, 278-281
101. Ribeiro, M. O., Antunes, E., de Nucci, G., Lovisolo, S. M. and Zatz, R. (1992) Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20, 298-303
102. Arnal, J. F., Warin, L. and Michel, J. B. (1992) Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 90, 647-652
103. Lahera, V., Salazar, J., Salom, M. G. and Romero, J. C. (1992) Deficient production of nitric oxide induces volume-dependent hypertension. J. Hypertens. 10, S173-S177
104. Tsukamoto, O., Minamino, T., Sanada, S., Okada, K., Hirata, A., Fujita, M., Shintani, Y., Yulin, L., Asano, Y., Takashima, S. et al. (2006) The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc. Drugs Ther. 20, 93-102
105. Rude, M. K., Duhaney, T. A., Kuster, G. M., Judge, S., Heo, J., Colucci, W. S., Siwik, D. A. and Sam, F. (2005) Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46, 555-561
106. Fullerton, M. J. and Funder, J. W. (1994) Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc. Res. 28, 1863-1867
107. Grohe, C., Kahlert, S., Lobbert, K., Stimpel, M., Karas, R. H., Vetter, H. and Neyses, L. (1997) Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 416, 107-112
108. Beato, M. and Klug, J. (2000) Steroid hormone receptors: an update. Hum. Reprod. Update. 6, 225-236
109. Gurgen, D., Hegner, B., Kusch, A., Catar, R., Chaykovska, L., Hoff, U., Gross, V., Slowinski, T., da Costa Goncalves, A. C., Kintscher, U. et al. (2011) Estrogen receptor-ß signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice. Hypertension 57, 648-654
110. Gurgen, D., Kusch, A., Klewitz, R., Hoff, U., Catar, R., Hegner, B., Kintscher, U., Luft, F. C. and Dragun, D. (2013) Sex-specific mTOR signaling determines sexual dimorphism in myocardial adaptation in normotensive DOCA-salt model. Hypertension 61, 730-736
111. Karatas, A., Hegner, B., de Windt, L. J., Luft, F. C., Schubert, C., Gross, V., Akashi, Y. J., Gurgen, D., Kintscher, U., da Costa Goncalves, A. C. et al. (2008) Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 51, 1177-1183
112. Lange, D. L., Haywood, J. R. and Hinojosa-Laborde, C. (1998) Role of the adrenal medullae in male and female DOCA-salt hypertensive rats. Hypertension 31, 403-408
113. Ouchi, Y., Share, L., Crofton, J. T., Iitake, K. and Brooks, D. P. (1987) Sex difference in the development of deoxycorticosterone-salt hypertension in the rat. Hypertension 9, 172-177
114. Michaelis, M., Hofmann, P. J., Gotz, F., Bartel, C., Kienitz, T. and Quinkler, M. (2012) Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats. Horm. Metab. Res. 44, 291-295
115. Duprez, D. A. (2004) Is the female heart more sensitive to aldosterone for early remodeling? Hypertension 43, 936-937
116. Vasan, R. S., Evans, J. C., Benjamin, E. J., Levy, D., Larson, M. G., Sundstrom, J., Murabito, J. M., Sam, F., Colucci, W. S. and Wilson, P. W. (2004) Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43, 957-962
117. Schunkert, H., Hense, H. W., Muscholl, M., Luchner, A., Kurzinger, S., Danser, A. H. and Riegger, G. A. (1997) Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 77, 24-31
118. Rossier, M. F., Python, M. and Maturana, A. D. (2010) Contribution of mineralocorticoid and glucocorticoid receptors to the chronotropic and hypertrophic actions of aldosterone in neonatal rat ventricular myocytes. Endocrinology 151, 2777-2787
119. Maturana, A., Lenglet, S., Python, M., Kuroda, S. and Rossier, M. F. (2009) Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes. Endocrinology 150, 3726-3734
120. Gomez, A. M., Rueda, A., Sainte-Marie, Y., Pereira, L., Zissimopoulos, S., Zhu, X., Schaub, R., Perrier, E., Perrier, R., Latouche, C. et al. (2009) Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 119, 2179-2187
121. Ouvrard-Pascaud, A., Sainte-Marie, Y., Benitah, J. P., Perrier, R., Soukaseum, C., Nguyen Dinh Cat, A., Royer, A., Le Quang, K., Charpentier, F., Demolombe, S. et al. (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025-3033
122. Perrier, E., Kerfant, B. G., Lalevee, N., Bideaux, P., Rossier, M. F., Richard, S., Gomez, A. M. and Benitah, J. P. (2004) Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110, 776-783
123. Stein, M., Boulaksil, M., Jansen, J. A., Herold, E., Noorman, M., Joles, J. A., van Veen, T. A., Houtman, M. J., Engelen, M. A., Hauer, R. N. et al. (2010) Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol. 299, H310-321
124. Benitah, J. P. and Vassort, G. (1999) Aldosterone upregulates Ca2+ current in adult rat cardiomyocytes. Circ. Res. 85, 1139-1145
125. Benitah, J. P., Perrier, E., Gomez, A. M. and Vassort, G. (2001) Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J. Physiol. 537, 151-160
126. Wagner, M., Rudakova, E. and Volk, T. (2008) Aldosterone-induced changes in the cardiac L-type Ca2+ current can be prevented by antioxidants in vitro and are absent in rats on low salt diet. Pflugers Arch. 457, 339-349
127. Rougier, J. S., Muller, O., Berger, S., Centeno, G., Schutz, G., Firsov, D. and Abriel, H. (2008) Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. Pflugers Arch. 456, 407-412
128. Lalevee, N., Rebsamen, M. C., Barrere-Lemaire, S., Perrier, E., Nargeot, J., Benitah, J. P. and Rossier, M. F. (2005) Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc. Res. 67, 216-224
129. Le Menuet, D., Munier, M., Meduri, G., Viengchareun, S. and Lombes, M. (2010) Mineralocorticoid receptor overexpression in embryonic stem cell-derived cardiomyocytes increases their beating frequency. Cardiovasc. Res. 87, 467-475
130. Yee, K. M. and Struthers, A. D. (1998) Aldosterone blunts the baroreflex response in man. Clin. Sci. 95, 687-692
131. Zhang, R. L., Christensen, L. P. and Tomanek, R. J. (2010) Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat. Rec. 293, 839-848
132. Ovaert, P., Elliott, J., Bernay, F., Guillot, E. and Bardon, T. (2010) Aldosterone receptor antagonists: how cardiovascular actions may explain their beneficial effects in heart failure. J. Vet. Pharmacol. Ther. 33, 109-117
133. Xue, B., Beltz, T. G., Yu, Y., Guo, F., Gomez-Sanchez, C. E., Hay, M. and Johnson, A. K. (2011) Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am. J. Physiol. Heart Circ. Physiol. 300, H555-H564
134. Wenzel, S., Tastan, I., Abdallah, Y., Schreckenberg, R. and Schluter, K. D. (2010) Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism. Basic Res. Cardiol. 105, 247-256
135. Matsui, S., Satoh, H., Kawashima, H., Nagasaka, S., Niu, C. F., Urushida, T., Katoh, H., Watanabe, Y. and Hayashi, H. (2007) Non-genomic effects of aldosterone on intracellular ion regulation and cell volume in rat ventricular myocytes. Can. J. Physiol. Pharmacol. 85, 264-273
136. Mihailidou, A. S., Loan Le, T. Y., Mardini, M. and Funder, J. W. (2009) Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54, 1306-1312
137. Barbato, J. C., Mulrow, P. J., Shapiro, J. I. and Franco-Saenz, R. (2002) Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 40, 130-135
138. Barbato, J. C., Rashid, S., Mulrow, P. J., Shapiro, J. I. and Franco-Saenz, R. (2004) Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension 44, 751-757
139. Ferron, L., Ruchon, Y., Renaud, J. F. and Capuano, V. (2011) T-type Ca2+ signalling regulates aldosterone-induced CREB activation and cell death through PP2A activation in neonatal cardiomyocytes. Cardiovasc. Res. 90, 105-112
140. Ruchon, Y., Ferron, L., Sankhe, S., Renaud, J. F. and Capuano, V. (2012) T-type Ca2+ signalling downregulates MEK1/2 phosphorylation and cross-talk with the RAAS transcriptional response in cardiac myocytes. J. Mol. Cell Cardiol. 53, 291-298
141. De Mello, W. C. and Gerena, Y. (2008) Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. Regul. Pept. 151, 54-60
142. Chai, W., Garrelds, I. M., de Vries, R. and Danser, A. H. (2006) Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 47, 665-670
143. Hausenloy, D. J., Tsang, A., Mocanu, M. M. and Yellon, D. M. (2005) Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 288, H971-H976
144. Schmidt, K., Tissier, R., Ghaleh, B., Drogies, T., Felix, S. B. and Krieg, T. (2010) Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur. Heart J. 31, 1655-1662
145. Kanashiro-Takeuchi, R. M., Heidecker, B., Lamirault, G., Dharamsi, J. W. and Hare, J. M. (2009) Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. Clin. Transl. Sci. 2, 134-142
146. Saraste, A., Pulkki, K., Kallajoki, M., Henriksen, K., Parvinen, M. and Voipio-Pulkki, L. M. (1997) Apoptosis in human acute myocardial infarction. Circulation 95, 320-323
147. Pierdominici, M., Ortona, E., Franconi, F., Caprio, M., Straface, E. and Malorni, W. (2011) Gender specific aspects of cell death in the cardiovascular system. Curr. Pharm. Des. 17, 1046-1055
148. Mano, A., Tatsumi, T., Shiraishi, J., Keira, N., Nomura, T., Takeda, M., Nishikawa, S., Yamanaka, S., Matoba, S., Kobara, M. et al. (2004) Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 110, 317-323
149. Loan Le, T. Y., Mardini, M., Howell, V. M., Funder, J. W., Ashton, A. W. and Mihailidou, A. S. (2012) Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension 59, 1164-1169
150. Hayashi, H., Kobara, M., Abe, M., Tanaka, N., Gouda, E., Toba, H., Yamada, H., Tatsumi, T., Nakata, T. and Matsubara, H. (2008) Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 31, 363-375